Search

While sugar gets most of the attention as a cancer fuel, other nutrients can be equally important.

… Wednesday, April 24, 2019 Summary Like all cells, cancer cells need nutrients to grow. Sugar is one important fuel, but it’s far from cancer’s only requirement. Current research is aimed at targeting cancer’s dependence on the amino acid glutamine as a weakness. In 1955, an American doctor named Harry

Learn how people facing metastatic breast cancer help each other in support groups at Memorial Sloan Kettering.

… Thursday, July 1, 2021 For Reilly Starr, the relationships inside her support group are nearly impossible to describe — or for people outside to comprehend. “It’s hard to say that these people are just friends,” she says. “The relationships are so deep. They are really like another treatment for your

Find ways to cope with cancer during the holiday season.

… Wednesday, December 8, 2021 It’s the most wonderful time of the year. Except when it isn’t. Coping with cancer is already hard. Coping with cancer during the holidays can be even more difficult, especially for teens and young adults with cancer, who are excited about developing plans for their future

Learn about Daniel Heller, who creates new nanoscale materials that are specially designed to improve biological research or solve clinical problems.

… Thursday, March 27, 2014 VIDEO | 02:26 Tiny Solutions for Big Problems: A Visit to the Lab of Daniel Heller Chemist Daniel Heller’s lab creates new nanoscale materials that are specially designed to speed developments in cancer research, diagnosis, and treatment. Video Details Summary The research team

Since 2007, Cycle for Survival donors and participants have raised more than $400 million to accelerate life-changing rare cancer research at Memorial Sloan Kettering Cancer Center.

… Wednesday, February 26, 2025 Cycle for Survival, the official rare cancer fundraising program of Memorial Sloan Kettering Cancer Center (MSK), is thrilled to announce a historic milestone in the movement to beat rare cancers: $400 million raised since the program began in 2007. All the money has funded

A clinical trial of the targeted therapy mosunetuzumab (Lunsumio) has found this drug may help patients with follicular lymphoma avoid chemotherapy. Learn more about how it benefited patients who had not yet received other treatments for their lymphoma.

… Monday, December 11, 2023 Thanks to a clinical trial (research study) of a targeted immunotherapy drug called mosunetuzumab (Lunsumio™), Anne Schmiedel is now in remission from follicular lymphoma . “These days I feel really good,” Anne says. “My energy levels are good, and I’m able to do everything

Visible Ink, a writing program for MSK patients that pairs them with professional mentors, held its tenth anniversary live performance.

… Friday, April 20, 2018 Summary Visible Ink, a writing program for MSK patients that pairs them with professional mentors, held its tenth anniversary live performance. As the lights dimmed on the Kaye Playhouse at Hunter College, the sellout crowd of hundreds hushed and turned their attention to the stage

Early detection helps improve patient outcomes, but data shows that many cancers are going undiagnosed or untreated because of COVID-19.

… Thursday, January 28, 2021 On January 28, 2021, Memorial Sloan Kettering (MSK) and more than 75 national cancer centers and organizations endorsed an open letter from the National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) urging Americans to resume regular cancer screenings

Read highlights of research presented by MSK scientists at the annual ASH meeting.

… Monday, December 9, 2024 Research advances in lymphoma, leukemia, and multiple myeloma are being presented by Memorial Sloan Kettering Cancer Center (MSK) researchers at the  American Society of Hematology (ASH) Annual Meeting , which runs December 7–10. Below are some highlights. Dual-Targeting of JAK

A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon.

… Saturday, May 30, 2009 A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don’t require immediate surgery to remove the primary tumor in the colon. Researchers from Memorial Sloan Kettering Cancer Center (MSKCC) presented